公开(公告)号：US20230114683A1

公开(公告)日：2023-04-13

申请号：US17792837

申请日：2021-02-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Saleem Ahmad ,  Lidet A. Negash

IPC: C07D471/04 ,  C07D471/14

Abstract: Disclosed are compounds of Formulas (I) or (II) or a salt thereof, wherein X, R1, R2, R3, and n are defined herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

公开(公告)号：US10538505B2

公开(公告)日：2020-01-21

申请号：US16407441

申请日：2019-05-09

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Saleem Ahmad

IPC: C07D401/04 ,  A61K45/06 ,  C07D417/14 ,  C07D401/14 ,  C07D409/14 ,  A61K31/4439

Abstract: The present invention provides compounds of Formula (I): a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：US20190314346A1

公开(公告)日：2019-10-17

申请号：US16445913

申请日：2019-06-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Huji Turdi ,  Jon J. Hangeland ,  R. Michael Lawrence ,  Saleem Ahmad ,  Wei Meng ,  Robert Paul Brigance ,  Pratik Devasthale ,  Guohua Zhao

IPC: A61K31/438 ,  C07F9/59 ,  C07D401/10 ,  C07D401/14 ,  A61K31/5377 ,  C07D413/14 ,  C07D221/20 ,  C07D413/04 ,  A61K31/4439 ,  C07D401/04 ,  A61K31/4418 ,  C07D211/90 ,  A61K31/675 ,  C07D405/14 ,  C07F9/40 ,  C07F9/535 ,  C07D211/86 ,  C07D417/14 ,  C07D417/04 ,  C07D413/12 ,  C07D407/14 ,  C07D401/12 ,  A61K45/06

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：US20190225583A1

公开(公告)日：2019-07-25

申请号：US16289878

申请日：2019-04-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Saleem Ahmad ,  Douglas G. Batt ,  Qingjie Liu ,  John E. Macor ,  Joseph A. Tino ,  Scott Hunter Watterson ,  Satheesh Kesavan Nair ,  Tarun Kumar Maishal

IPC: C07D209/88 ,  C07D495/04 ,  C07D403/12 ,  C07D471/10 ,  C07D487/04 ,  A61K31/4523 ,  C07D403/06 ,  C07D471/04 ,  C07D403/04 ,  C07D401/04 ,  C07D401/06

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein Q, R1a, R1b, R2a, R2b, R3, R4, R5a, R5b, R6a, R6c, R7a, R7b, R7c, and R7d are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

公开(公告)号：US20180133198A1

公开(公告)日：2018-05-17

申请号：US15867825

申请日：2018-01-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Huji Turdi ,  Jon J. Hangeland ,  R. Michael Lawrence ,  Saleem Ahmad ,  Wei Meng ,  Robert Paul Brigance ,  Pratik Devasthale ,  Guohua Zhao

IPC: A61K31/438 ,  C07F9/59 ,  A61K31/4418 ,  C07F9/40 ,  C07D417/14 ,  C07D417/04 ,  C07D413/14 ,  C07D413/12 ,  C07D413/04 ,  C07D407/14 ,  C07D405/14 ,  C07D401/14 ,  C07D401/12 ,  C07D401/10 ,  C07D401/04 ,  C07D221/20 ,  C07D211/90 ,  C07D211/86 ,  A61K45/06 ,  A61K31/675 ,  A61K31/5377 ,  A61K31/4439 ,  C07F9/535

CPC classification number: A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/675 ,  A61K45/06 ,  C07D211/86 ,  C07D211/90 ,  C07D221/20 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07F9/4006 ,  C07F9/5352 ,  C07F9/59

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：US09586900B2

公开(公告)日：2017-03-07

申请号：US14425507

申请日：2013-09-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Saleem Ahmad ,  Guohua Zhao ,  William N. Washburn

IPC: C07D207/273 ,  C07D207/327 ,  C07D401/12 ,  C07D409/12 ,  A61K31/4015 ,  A61K31/4025 ,  A61K31/4439 ,  C07D403/12 ,  C07D207/27

CPC classification number: C07D207/273 ,  C07D207/27 ,  C07D207/327 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12

Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may be used as medicaments.

Abstract translation: 本发明提供式（I）化合物：如说明书中所定义和包含任何这些新化合物的组合物。 这些化合物是可用作药物的黑色素浓缩激素受体-1（MCHR1）拮抗剂。

公开(公告)号：US09499482B2

公开(公告)日：2016-11-22

申请号：US14425165

申请日：2013-09-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： William N. Washburn ,  Murugaiah Andappan Murugaiah Subbaiah ,  Saleem Ahmad

IPC: A61K31/5377 ,  A61K31/4025 ,  A61K31/496 ,  A61K31/445 ,  A61K31/506 ,  A61K31/435 ,  A61K31/422 ,  A61K31/4178 ,  C07D207/273 ,  C07D403/12 ,  C07D401/14 ,  C07D401/12 ,  C07D403/14 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D491/10 ,  C07D295/096 ,  C07D295/135 ,  C07D491/107

CPC classification number: C07D207/273 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/422 ,  A61K31/435 ,  A61K31/445 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  C07D295/096 ,  C07D295/135 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D491/10 ,  C07D491/107

Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may be used as medicaments.

公开(公告)号：US20160115126A1

公开(公告)日：2016-04-28

申请号：US14921347

申请日：2015-10-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Qingjie Liu ,  Scott Hunter Watterson ,  Douglas G. Batt ,  Saleem Ahmad ,  Myra Beaudoin Bertrand ,  Hua Gong ,  Weiwei Guo ,  John E. Macor ,  Khehyong Ngu ,  Andrew J. Tebben ,  Joseph A. Tino

IPC: C07D209/08 ,  C07D403/10 ,  C07D403/12 ,  C07D403/04 ,  C07D487/10 ,  C07D487/04 ,  C07D413/04 ,  C07D471/04 ,  C07D401/06 ,  C07D417/04 ,  C07D401/04 ,  C07D401/12

CPC classification number: C07D401/10 ,  C07D209/08 ,  C07D209/18 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract translation: 公开了式（I）的化合物或其盐，其中：X是CR 4或N; R1，R2，R3，R4和A在本文中定义。 还公开了使用这种化合物作为Bruton酪氨酸激酶（Btk）的抑制剂的方法和包含这些化合物的药物组合物。 这些化合物可用于治疗，预防或减缓各种治疗领域（例如自身免疫性疾病和血管疾病）中的疾病或病症的进展。

公开(公告)号：US20160031816A1

公开(公告)日：2016-02-04

申请号：US14883067

申请日：2015-10-14

Applicant: Bristol-Myers Squibb Company

Inventor： Huji Turdi ,  Jon J. Hangeland ,  R. Michael Lawrence ,  Dong Cheng ,  Saleem Ahmad ,  Wei Meng ,  Robert Paul Brigance ,  Pratik Devasthale ,  Guohua Zhao

IPC: C07D211/90 ,  C07D221/20 ,  C07D401/10 ,  C07D401/04 ,  C07D405/14 ,  C07D401/14 ,  C07D211/86 ,  C07D417/04 ,  C07D413/12 ,  C07D401/12 ,  C07D413/04

CPC classification number: A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/675 ,  A61K45/06 ,  C07D211/86 ,  C07D211/90 ,  C07D221/20 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07F9/4006 ,  C07F9/5352 ,  C07F9/59

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：US08791091B2

公开(公告)日：2014-07-29

申请号：US13688584

申请日：2012-11-29

Applicant: Bristol-Myers Squibb Company

Inventor： Huji Turdi ,  Jon J. Hangeland ,  R. Michael Lawrence ,  Saleem Ahmad ,  Wei Meng ,  Robert Paul Brigance ,  Pratik Devasthale ,  Guohua Zhao

IPC: A61K31/675 ,  A61K31/4418 ,  A61K45/06 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/5377 ,  C07D401/04 ,  C07D413/04 ,  C07D413/14 ,  C07F9/59 ,  C07D401/14 ,  C07D211/90 ,  C07D221/20

CPC classification number: A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/675 ,  A61K45/06 ,  C07D211/86 ,  C07D211/90 ,  C07D221/20 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07F9/4006 ,  C07F9/5352 ,  C07F9/59

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

Abstract translation: 本发明提供式（I）化合物或其立体异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是可用作药物的单酰基甘油酰基转移酶2型（MGAT2）抑制剂。